AstraZeneca said the job cuts are a result of increased efficiencies following a multimillion-dollar upgrade at its plant in Macclesfield. Now, fewer employees are needed to maintain operations.
GMB Union, a local union representing the U.K. workers, called the decision a “hammer blow for manufacturing,” according to the report.
The campus in the U.K. where the job cuts will occur produces small-molecule drugs.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
